Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors.
about
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.Thrombocytopenia in association with splenomegaly during granulocyte-colony-stimulating factor treatment in mice is not caused by hypersplenism and is resolved spontaneously.Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization.Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: a state-of-the-art review.Allogeneic peripheral blood stem cell transplantation.Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation.Sleep disruption in critically ill patients--pharmacological considerations.Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection CentersNeuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I/IIa clinical trialCanadian supportive care recommendations for the management of neutropenia in patients with cancer.G-CSF in Healthy Allogeneic Stem Cell Donors.Cell therapy in peripheral arterial disease.The link between iron, metabolic syndrome, and Alzheimer's disease.Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?Hematopoietic stem cell donation.A review of the haematopoietic stem cell donation experience: is there room for improvement?Venous access for hematopoietic progenitor cell collection: An international survey by the ASFA HPC donor subcommittee.The role of donor characteristics and post-granulocyte colony-stimulating factor white blood cell counts in predicting the adverse events and yields of stem cell mobilization.Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience.Collection of peripheral blood progenitor cells on Day 4 is feasible and effective while reducing granulocyte-colony-stimulating factor exposure to healthy donors.Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.Granulocyte Colony-Stimulating Factor (G-CSF) for the Treatment of Spinal Cord Injury.Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors.Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue.Donor age-related differences in PBPC mobilization with rHuG-CSF.
P2860
Q31135878-60A06FC8-B53F-4B29-86EA-07B072C4DAC0Q33373777-C7BE3BE1-5401-473C-A631-924AA7E92354Q33389390-069B227B-473E-4778-8192-522C77B286CAQ34165168-98581EF7-330D-4A36-967D-26811543E2D7Q34326715-E93FE11C-6BF4-4509-ACA9-732B29C09989Q34975536-76D6AD46-0DE7-40A5-B7EF-D44AE44A8683Q35691907-0CE78DE5-AC0A-4CA3-B43B-8E8F6A975CCAQ36055063-52C7998C-F00C-443B-BDBF-885FF2C33684Q36428437-A3396C33-C581-4817-8235-01936790F520Q36485208-02DB5473-C1FC-4DBE-9982-F1155789D763Q37180718-319C3C6B-C70E-4F47-8553-CD9803D35876Q37279639-EFA2D932-090C-4F6F-9AE7-47F418CE588DQ37765832-CD1970E2-08A7-4FA9-B06A-1B0C798B3BBBQ37996560-C6C24E02-2188-482C-908F-F4E0C774646AQ38082689-0CA5C34A-B2C3-4F6C-88BC-8AC5281437D9Q38181958-61938D08-DB5A-43FF-9613-64E49D192DA0Q40112919-997F0551-DDF4-41C8-8338-6EB4AF95CD49Q40327354-BF6B863F-F21D-41C4-8BC9-8A7C12B5BFB6Q40398250-E643C2EC-1C14-4076-9A49-26D5881E1CD3Q41485866-62B1B020-58AA-4A84-A0BA-81D908F639AEQ46900519-5E8065A1-A53A-4FDF-AEFD-EB29754427CCQ47566621-2F035CAF-EA2B-4170-9006-F8128AE35199Q48192483-5A92D6D3-DFC2-4AFC-9851-E5B497CC23B5Q48916913-B3C7EBFB-42B6-4B7D-8909-7BC60D770F9AQ50128449-A7B85FA2-26B5-4648-B74C-4049787EA310
P2860
Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@ast
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@en
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@nl
type
label
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@ast
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@en
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@nl
prefLabel
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@ast
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@en
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@nl
P2093
P356
P1476
Peripheral blood stem cell mob ...... se events in 94 normal donors.
@en
P2093
Sakamaki H
Takahashi S
Tsuchiya S
P2888
P304
P356
10.1038/SJ.BMT.1702038
P407
P577
1999-11-01T00:00:00Z
P5875
P6179
1009010709